Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 4/20 | 0.32 |
| ▸ | CTSF | Q9UBX1 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370341 | 0.90 | CTSL (0.37) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL4364936 | 0.90 | TAS1R3 (0.38) | MAPTTDP1TAS1R3TAS1R1CTSK | |
| SCHEMBL4364927 | 0.90 | TAS1R3 (0.38) | MAPTTDP1TAS1R3TAS1R1CTSK | |
| SCHEMBL4367734 | 0.79 | CTSL (0.41) | TAS1R3TAS1R1CTSKCTSLALDH1A1 | |
| SCHEMBL4367724 | 0.79 | CTSL (0.41) | TAS1R3TAS1R1CTSKCTSLALDH1A1 | |
| SCHEMBL13624390 | 0.76 | CTSL (0.39) | TAS1R3TAS1R1CTSKCTSLALDH1A1 | |
| SCHEMBL13624172 | 0.76 | TAS1R3 (0.47) | TAS1R3TAS1R1CTSKCTSLCTSB | |
| SCHEMBL13624425 | 0.76 | CTSL (0.41) | TAS1R3TAS1R1CTSKCTSLALDH1A1 | |
| SCHEMBL13624409 | 0.74 | CTSK (0.42) | TAS1R3TAS1R1CTSKCTSL | |
| SCHEMBL13624321 | 0.74 | CTSL (0.57) | MAPTTDP1TAS1R3TAS1R1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | MAPT 480/4885TDP1 1784/4885TAS1R3 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.